Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC) – Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE...

Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial – Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS...

Global Hyperphosphatemia Market Size To Grow USD 4.2 Billion By 2030 | CAGR of 6.5% New York, United States , March 24, 2023 (GLOBE NEWSWIRE) -- The Global Hyperphosphatemia Market Size to grow from USD 3.1 Billion in 2021 to USD 4.2 Billion by 2030, at a Compound Annual Growth...

Hyperphosphatemia Therapeutics Market to Hit Sales of $3.53 Billion by 2028 | Over 93% Physicians Prefer Binders For Treating Hyperphosphatemia Westford, USA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hyperphosphatemia is a condition characterized by elevated levels of phosphate in the blood. Phosphate plays an important role in cell function...

Hyperphosphatemia Treatment Market Size | Is Projected to Reach USD 3.53 Billion in 2028 with CAGR 5.3% Pune, India, Aug. 16, 2021 (GLOBE NEWSWIRE) -- The global hyperphosphatemia treatment market size is projected to grow from USD 2.46 billion in 2021 and is expected to reach USD 3.53 billion in...